İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - dopamine hydrochloride - concentrate for solution for infusion - 40 milligram(s)/millilitre - adrenergic and dopaminergic agents; dopamine

İsrail - İngilizce - Ministry of Health

medic trim healthcare ltd - dopamine hydrochloride - solution for infusion - dopamine hydrochloride 200 mg / 5 ml - dopamine - to correct hemodynamic imbalances associated with myocardial infarction trauma septic shock and cardiac surgery. dopamine hydrochloride is used in the treatment of : 1. shock unresponsive to replacement of fluid loss and especially where renal function is impaired. 2. to correct haemodynamic imbalances associated with myocardial infarction trauma septic shock and cardiac surgery. 3. it is also used in the management of chtonic refractory congestive heart failure.

ABD - İngilizce - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride in 5% dextrose injection, usp is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure. when indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride. patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis. poor perfusion of vital organs: although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 ml/minute prognosis is more favorable. however, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. the drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect. low cardiac output: dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. increased output has been associated with unchanged or decreased systemic vascular resistance (svr). the association of static or decreased svr with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. in many instances the renal fraction of the total cardiac output has been found to increase. increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. hypotension: low to moderate doses of dopamine, which have little effect on svr, can be used to manage hypotension due to inadequate cardiac output. at high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished svr. as in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent. dopamine hydrochloride should not be used in patients with pheochromocytoma. dopamine should not be administered in the presence of uncorrected tachyarrhythmias or ventricular fibrillation. to open tear outer wrap at notch and remove solution container. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. preparation for administration (use aseptic technique) 1. close flow control clamp of administration set. 2. remove cover from outlet port at bottom of container. 3. insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. note: see full directions on administration set carton. 4. suspend container from hanger. 5. squeeze and release drip chamber to establish proper fluid level in chamber. 6. open flow control clamp and clear air from set. close clamp. 7. attach set to venipuncture device. if device is not indwelling, prime and make venipuncture. 8. regulate rate of administration with an infusion pump, preferably a volumetric pump. warning: do not use flexible container in series connections.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - dobutamine hydrochloride, quantity: 14.01 mg/ml - injection, intravenous infusion - excipient ingredients: sodium metabisulfite; water for injections - indicated in adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction,or cardiac surgery.

Kenya - İngilizce - Pharmacy and Poisons Board

verve human care laboratories 15-a, pharmacity, selaqui, dehradun-248011,india - dobutamine hydrochloride usp - solution for injection - each ml contains: dobutamine hydrochloride usp… - dobutamine

Malta - İngilizce - Malta Medicines Authority

mercury pharmaceuticals (ireland) limited 4045 kingswood road, city west business park, co, dublin, ireland - dobutamine - concentrate for solution for infusion - dobutamine 12.5 mg/ml - cardiac therapy

Malezya - İngilizce - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - dobutamine hydrochloride -

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - dobutamine hydrochloride 280mg equivalent to 250 mg dobutamine;  ;   - solution for infusion - 250 mg - active: dobutamine hydrochloride 280mg equivalent to 250 mg dobutamine     excipient: sodium metabisulfite water for injection

Ermenistan - İngilizce - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

laboratorio medinfar-produtos farmaceuticos - dopamine (dopamine hydrochloride) - solution for infusion - 200mg/5ml

ABD - İngilizce - NLM (National Library of Medicine)

hikma farmaceutica - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) -